

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q3 12-13	Q3 11-12	% Gr y-y	YTD 12-13	YTD 11-12	% Gr y-y
Domestic	7,377	6,058	21.8%	22467	18103	24.1%
Formulations	5,699	4,693	21.4%	17,534	13,966	25.5%
API	160	157	1.9%	384	291	32.0%
Wellness	1,018	796	27.9%	3,016	2,588	16.5%
Animal Health & Others	500	412	21.4%	1,533	1,258	21.9%
Exports	7,302	6,467	12.9%	20,530	16,822	22.0%
Formulations	6,562	5,783	13.5%	18,334	14,812	23.8%
US	3,920	3,435	14.1%	11,186	8,898	25.7%
Europe	1,119	889	25.9%	2,736	2,277	20.2%
Japan	180	154	17.0%	462	386	19.8%
Brazil	666	792	-15.9%	1,797	1,917	-6.3%
Emerging Mkts & Others	677	513	31.8%	2,153	1,334	61.3%
API	618	577	7.2%	1,856	1,819	2.0%
Animal Health & Others	122	107	14.3%	340	191	78.2%
JVs	1,263	1,212	4.2%	3,859	3,089	24.9%
Total	15,942	13,736	16.1%	46,855	38,014	23.3%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q3 12-13	Q3 11-12	% Gr y-y	YTD 12-13	YTD 11-12	% Gr y-y
Other Operating Income	431	307	40.4%	1,566	1,196	30.9%
Dossier Fees	0	2	-100.0%	2	495	-99.6%
Royalty Income	0	107	-100.0%	296	213	39.0%
Net Gain on foreign currency transactions and translation (Refer Note below)	117	0		593	0	
Others	314	198	58.6%	675	488	38.3%

Note : Apart from this gain, there was a net gain of Rs. 82 Mio. in Q3 12-13 on hedging and on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods. Thus, on aggregate level, there was a gain of Rs. 199 Mio. on operating transactions (above EBIDTA line) in Q3 12-13 vs gain of Rs. 202 Mio. in Q3 11-12. See details below for more clarity.

Rs. Mio.	Q3 12-13	Q3 11-12	% Gr y-y	YTD 12-13	YTD 11-12	% Gr y-y
Other Income	171	182	-6.3%	330	356	-7.2%
Interest & Dividend income	125	83	50.6%	265	226	17.0%
Profit on sale of investments	9	53	-83.8%	14	58	-75.5%
Profit on sale of assets	0	-3	100.0%	0	9	-100.0%
Others	37	49	-24.5%	51	63	-18.6%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q3 12-13	Q3 11-12	% Gr y-y	YTD 12-13	YTD 11-12	% Gr y-y
A. On operating transactions (above EBIDTA line)	-199	-202	1.5%	-15	-126	88.1%
a. Included in other income (as shown above)	-117	0		-593	0	
b. Included in cost of goods	-82	-226	63.7%	578	-444	230.2%
c. Included in other expenses		24	-100.0%		318	-100.0%
B. On Foreign Currency Borrowings (part of interest cost)	33	318	-89.5%	437	769	-43.2%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	-166	116	-243.1%	422	643	-34.4%

Details of Revenue R&D Expenses

Rs. Mio.	Q3 12-13	Q3 11-12	% Gr y-y	YTD 12-13	YTD 11-12	% Gr y-y
Total Revenue R&D Expenses (incl. HR Cost)	1,381	1,115	24%	3,425	2,717	26%

Consolidated Capex for Apr-Dec 12

Rs. 5980
Mio.

R&D capex included in above for Apr-Dec 12 :

Rs. 450
Mio.